Free tool
Oncology stocks
We cover 45 companies grouped under the Oncology theme. The median market value in the group is $4.67B. Across the group, the median move over the past trading day is +1.63%. 82% of the 44 with a 200-day average trade above it. Price change over the past year runs from −22.3% to +333.2% across the middle 80 percent of the group, with a median of +53.5%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
45 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $138.74B | Large cap | +49.31% |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $73.00B | Large cap | +12.47% |
| RVMD | Revolution Medicines, Inc. | $45.35B | Large cap | +492.60% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +21.95% |
| 4568.T | Daiichi Sankyo Company, Limited | $33.36B | Large cap | −15.95% |
| BNTX | BioNTech SE | $28.65B | Large cap | +8.55% |
| INCY | Incyte Corporation | $26.29B | Large cap | +53.04% |
| GMAB | Genmab A/S | $21.42B | Large cap | +41.34% |
| GE9.DE | GENMAB AS N | $21.11B | Large cap | −14.41% |
| 0J9P.L | Incyte Corporation | $21.10B | Large cap | +53.55% |
| IPN.PA | Ipsen S.A. | $16.01B | Large cap | +39.21% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +49.66% |
| 0IJO.L | Exelixis, Inc. | $14.05B | Large cap | +44.33% |
| 0M2N.L | Orion Oyj | $11.16B | Large cap | +19.68% |
| SMMT | Summit Therapeutics Inc. | $10.66B | Large cap | −49.14% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +67.40% |
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.39B | Mid cap | +62.22% |
| CGON | CG Oncology, Inc. | $7.00B | Mid cap | +210.58% |
| E2XE34.SA | Exelixis, Inc. | $6.61B | Mid cap | +23.92% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +79.61% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +212.13% |
| ERAS | Erasca, Inc. | $6.16B | Mid cap | +1016.98% |
| 000100.KS | Yuhan Corporation | $4.67B | Mid cap | −25.59% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $4.54B | Mid cap | +75.99% |
| RLAY | Relay Therapeutics, Inc. | $4.51B | Mid cap | +486.04% |
| ELVN | Enliven Therapeutics, Inc. | $4.48B | Mid cap | +205.89% |
| CELC | Celcuity Inc. | $4.44B | Mid cap | +87.35% |
| TNGX | Tango Therapeutics, Inc. | $4.13B | Mid cap | +264.73% |
| IDYA | IDEAYA Biosciences, Inc. | $4.10B | Mid cap | +71.91% |
| RCUS | Arcus Biosciences, Inc. | $4.02B | Mid cap | +211.03% |
| TLX | Telix Pharmaceuticals Limited | $3.96B | Mid cap | −4.26% |
| TLX.AX | Telix Pharmaceuticals Limited | $3.91B | Mid cap | −12.72% |
| 000105.KS | Yuhan Corporation | $3.88B | Mid cap | −31.05% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +196.22% |
| ZLAB | Zai Lab Limited | $2.94B | Mid cap | −23.10% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.89B | Mid cap | +637.70% |
| NRIX | Nurix Therapeutics, Inc. | $2.73B | Mid cap | +178.70% |
| NUVB | Nuvation Bio Inc. | $2.49B | Mid cap | +146.53% |
| URGN | UroGen Pharma Ltd. | $2.27B | Mid cap | +150.59% |
| XNCR | Xencor, Inc. Common Stock | $2.18B | Mid cap | +265.79% |
| HCM | HUTCHMED (China) Limited | $2.13B | Mid cap | −23.04% |
| HCM.L | HUTCHMED (China) Limited | $2.12B | Mid cap | −21.24% |
| NANO.PA | Nanobiotix S.A. | $2.12B | Mid cap | +341.09% |
| NBTX | Nanobiotix S.A. | $2.11B | Mid cap | +321.42% |
| NVCR | NovoCure Limited | $2.05B | Mid cap | +50.60% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.